Morinaga Milk Expands Lactoferrin Production Capacity in German Subsidiary “MILEI GmbH”
28.10.2020 08:52:00 EET | Business Wire | Press release
Morinaga Milk Industry Co., Ltd. (TOKYO: 2264) (hereafter, “Morinaga Milk”) hereby announces that its subsidiary MILEI GmbH (hereafter, “MILEI”), which has the largest share* of the global market in terms of production volume of the functional ingredient lactoferrin, will increase more than double its production capacity with the aim to enhance its lactoferrin production.
* According to data for 2019 released by Absolute Reports
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027006307/en/
Powdered lactoferrin (Photo: Morinaga Milk)
1. Overview
(1) Location: Kemptener Strasse 91, 88299 Leutkirch, Germany
(2) Product manufactured: Lactoferrin
(3) Total investment: EUR 15,000,000 (approx. JPY 1.8 billion*) * Assuming an exchange rate of 120 yen to one euro
(4) Production capacity: Approx. 170 tons (more than double that of fiscal 2019)
(5) Launch of operations: April 2021 (planned)
2. Background and purpose
As a functional ingredient for infant formula, supplements and other foods, the demand for lactoferrin has been growing particularly in Western countries and Asia.
Considering the increasing attention towards health and nutrition, the demand for lactoferrin as a functional ingredient with health value is expected to grow over the long term globally.
Morinaga Milk Group considers lactoferrin as an important functional ingredient to support people’s health and nutrition worldwide and has been conducting fundamental research and seeking commercial applications for over six decades.
Morinaga Milk Group is aiming to increase the sales of its own lactoferrin-related products with expanding production capacity in MILEI, and will flexibly respond to the long-term increasing demand of lactoferrin.
Having the largest production share of lactoferrin, Morinaga Milk Group will increase the production of MILEI and contribute to the well-being of people.
3. Effect on financial results
The investment will not affect financial results for the fiscal year ending March 31, 2021.
[Reference information]
MILEI GmbH
MILEI is based in the southern German city of Leutkirch, where its production facilities are located.
Founded in 1972, MILEI has a history of almost five decades since its start of production in 1975. MILEI offers lactoferrin, whey protein concentrate, lactose and other dairy ingredients mainly in Europe and Asia. Many companies, including global food manufacturers, use MILEI’s ingredients for infant formula, sports nutrition and others. Under the global strategy of Morinaga Milk, MILEI plays an important role supporting production and sales of ingredients for infant formula, supplements and others.
Lactoferrin
Present in most exocrine secretions such as breast milk and saliva of humans and other mammals, lactoferrin is a component with a wide range of physiological functions. The high amount of lactoferrin found in human breast milk, especially in colostrum, is considered to offer important and protective benefits to newborns.
Discovered by Danish scientists in 1939, lactoferrin as a remarkable functional ingredient, has been intensively researched by scientists worldwide, as shown by the increasing number of the studies in the graph (Figure 1). Paying high attention to the fact that lactoferrin is highly abundant in colostrum, Morinaga Milk has been focusing its research efforts on lactoferrin over the long term to develop infant formula that closely resembles breast milk. Since its initial publication of a research paper on lactoferrin in 1963, Morinaga Milk has been reporting its benefits through academic forums, conferences and publications.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027006307/en/
Contact information
International Division, Morinaga Milk Industry Co., Ltd.
Yoshihiko Ushida
Tamami Shibata
TEL: +81-3-3798-0152
E-mail: interntl@morinagamilk.co.jp
https://www.morinagamilk.co.jp/english/
https://www.milei.de (MILEI GmbH Website)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SuperElastic* Material Unveiled by Angelalign2.11.2026 19:46:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”)http://www.angelaligner.com, a global clear aligner leader, today unveiled SuperElastic (MC-SE*), a new propietary aligner material that is a significant breakthrough in performance over its current material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102654659/en/ Specialists in orthodontics have long asked for new aligner materials that enable better treatment for complex cases: biologically safe force levels, a large elastic working range, and strength and toughness. MC-SE* provides all of them. “Angel is commited to innovation and never settling for 'good enough'. MC-SE* is the result of seven years of materials research, testing and manufacturing optimization. The new material aims to create a new generation of aligner material that allows orthodonists to differentiate their treatment from other treatments,“ said Fox Hu, CEO of Angel. MC-SE will be available globally
Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition2.11.2026 19:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced proposed changes to its Board of Directors, aimed at further strengthening its governance and supporting its long-term growth. The company also announced that Luigi La Corte, Chief Financial Officer (CFO), has decided to leave Galderma to pursue a significant new opportunity. Luigi La Corte will continue to fulfil his responsibilities as CFO during the transition period, supporting business continuity and a smooth handover. The company will communicate further details regarding succession arrangements and the transition timeline in due course. The Board of Directors is proposing the election of Rosalind Brewer and Petra Rumpf as new Board members. Both candidates bring extensive leadership and governance experience, alongside expertise spanning consumer-facing businesses, healthcare, medtech and life sciences. As Galderma advances its ambition to become the undisputed dermatology powerhouse, spanni
Donaldson Introduces Alpha-Pore™ Technology Platform for Extended Sterile Filtration Performance2.11.2026 16:35:00 EET | Press release
Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of innovative filtration products and solutions, today announced Alpha‑Pore™ technology, a next generation sterile filtration platform engineered to extend filter service life while maintaining critical process performance. Built for critical applications, Alpha‑Pore technology enables longer filter run time compared with competitive single- and dual-layer polyethersulfone (PES) membrane filters, while maintaining flow characteristics, sterility assurance, and process integrity.* The platform is designed to help manufacturers improve operational efficiency through fewer changeouts and more consistent performance over time. Engineered for Extended Performance Sterile filtration processes often require balancing run time with key performance parameters such as flow, differential pressure, and contaminant retention. Alpha‑Pore technology is designed to achieve all three. By optimizing pore structure and filter architect
Smartly Launches Intelligence Pro to Connect Campaign Planning, Performance and Incrementality2.11.2026 16:00:00 EET | Press release
Smartly, the AI-powered advertising technology company, today launched Intelligence Pro, a premium offering that brings together four capabilities to help marketers plan investment, understand true incrementality and determine where to spend their next dollar. Intelligence Pro connects causal inference models with planning tools to help marketers prove business impact and make faster decisions from increasingly complex data. “Marketing teams are inundated with data, but the challenge is identifying what signals are useful and turning them into a decision they can act on,” said Maxwell Tang, Chief Product Officer at Smartly. “Intelligence Pro brings forecasting, market context and state-of-the-art incrementality signals together to help marketers assess where to invest and what their media is contributing. As AI accelerates campaign execution, the quality of each decision matters more.” Intelligence Pro combines four capabilities within Smartly’s platform: Reach Planner helps teams comp
SBC Medical Forms Capital and Business Alliance with AtomicSoftware, Provider of the medicalforce Clinic Management Platform Used by 800+ Clinics in Japan2.11.2026 16:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it entered into a capital and business alliance agreement on October 26, 2026, with AtomicSoftware Inc. (“AtomicSoftware”), the Tokyo-based provider of medicalforce, an all-in-one software-as-a-service (SaaS) platform for clinics. In connection with the alliance, SBC Medical has invested ¥600 million (approximately US$3.8 million) in AtomicSoftware’s Series C funding round. The two companies will co-develop AI features, beginning with a feature that supports physicians in preparing medical records. Key Highlights Proven platform: medicalforce is used by more than 800 clinics*1 in Japan, primarily self-pay clinics, with a clinic retention rate of 99.2%*2. Joint AI development: Features co-developed by the two companies will enhance medicalforce and be progressively incorpo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
